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Abstract 
Background: We previously demonstrated that the HLA class II transactivator CIITA inhibits HIV-1 replication in T 
cells by competing with the viral transactivator Tat for the binding to Cyclin T1 subunit of the P-TEFb complex. Here, 
we analyzed the anti-viral function of CIITA in myeloid cells, another relevant HIV-1 target cell type. We sinvestigated 
clones of the U937 promonocytic cell line, either permissive (Plus) or non-permissive (Minus) to HIV-1 replication. This 
different phenotype has been associated with the expression of TRIM22 in U937 Minus but not in Plus cells.
Methods: U937 Plus cells stably expressing CIITA were generated and HLA-II positive clones were selected by cell 
sorting and cloning. HLA and CIITA proteins were analyzed by cytofluorometry and western blotting, respectively. 
HLA-II DR and CIITA mRNAs were quantified by qRT-PCR. Tat-dependent transactivation was assessed by perform-
ing the HIV-1 LTR luciferase gene reporter assay. Cells were infected with HIV-1 and viral replication was evaluated by 
measuring the RT activity in culture supernatants.
Results: CIITA was expressed only in HLA-II-positive U937 Minus cells, and this was strictly correlated with inhibition 
of Tat-dependent HIV-1 LTR transactivation in Minus but not in Plus cells. Overexpression of CIITA in Plus cells restored 
the suppression of Tat transactivation, confirming the inhibitory role of CIITA. Importantly, HIV-1 replication was signifi-
cantly reduced in Plus-CIITA cells with respect to Plus parental cells. This effect was independent of TRIM22 as CIITA did 
not induce TRIM22 expression in Plus-CIITA cells.
Conclusions: U937 Plus and Minus cells represent an interesting model to study the role of CIITA in HIV-1 restric-
tion in the monocytic/macrophage cell lineage. The differential expression of CIITA in CIITA-negative Plus and CIITA-
positive Minus cells correlated with their capacity to support or not HIV-1 replication, respectively. In Minus cells CIITA 
targeted the viral transactivator Tat to inhibit HIV-1 replication. The generation of Plus-CIITA cells was instrumental to 
demonstrate the specific contribution of CIITA in terms of inhibition of Tat activity and HIV-1 restriction, independently 
from other cellular factors, including TRIM22. Thus, CIITA acts as a general restriction factor against HIV-1 not only in T 
cells but also in myeloid cells.
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Background
The human immunodeficiency virus-1 (HIV-1) is a dev-
astating retrovirus that causes a severe immunologic 
deficiency known as acquired immunodeficiency syn-
drome (AIDS) [1]. HIV-1 eradication represents a cur-
rent topic and a long-term challenge in the study of 
human viral infection [2]. HIV-1 infection causes a dra-
matic impairment of the host immune system mainly 
characterized by the depletion of CD4+  T helper (Th) 
cells [3]. Moreover, soon after infection discrete cell res-
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are formed, in which the virus is latent or replicates at 
very low levels. These reservoirs are resistant even to 
combination anti-retroviral therapy (cART) and are 
responsible for the ignition of viral replication and dis-
ease progression at therapy suspension [4]. Myeloid cells 
such as dendritic cells (DC) and tissue macrophages play 
a crucial role in HIV-1 primary infection by capturing the 
virus through mucosal transmission [5] and subsequently 
by promoting virus dissemination to Th lymphocytes [6]. 
In addition, macrophages are resistant to the cytopathic 
effects of the virus, have a long lifespan and can dissemi-
nate the virus for long periods of time [7]. In peripheral 
blood, among the different populations of monocytes, 
the CD14+  CD16+  subset, which normally represents 
10  % of total monocytes, is more susceptible to HIV-
infection ex  vivo and can increase up to 50  % in HIV-1 
infected subjects in comparison to CD14+  CD16− 
monocytes that are dominant in healthy conditions [8]. 
Thus, the CD14+  CD16+  monocytes play a key role in 
virus dissemination and may contribute to establish-
ing HIV-1 reservoirs in various sites including the brain 
[9]. The susceptibility to HIV-1 infection of myeloid cells 
strongly depends on their differentiation stage. Circulat-
ing monocytes, although being CD4 and CCR5 positive, 
are less permissive to the virus than their differentiated 
macrophage counterpart, likely because of high levels of 
basal expression of restriction factors such as apolipopro-
tein B mRNA editing enzyme, catalytic polypeptide-like 
A (APOBEC3A) [10, 11]. In this regard, many restriction 
factors have been discovered in last decade which inhibit 
different steps of the viral life cycle from capsid uncoat-
ing to viral budding. Of note is the fact that most of these 
factors are inducible by interferons, including interferon 
gamma (IFN-γ) [12–18]. The importance of restriction 
factors is highlighted by the observation that HIV-1 has 
evolved the so-called “accessory proteins”, such as Nef, 
Vif, Vpu and, in case of HIV-2, VpX, to antagonize the 
antiviral effects of host restriction factors [13].
In this scenario, our laboratory has previously iden-
tified a cellular protein with the unique peculiarity of 
combining the activation of both the adaptive and the 
intrinsic immune responses against viral pathogens. This 
factor encoded by the Air-1 locus and named CIITA 
(Class II Transactivator) is indeed the master transcrip-
tional regulator of HLA (Human Leucocytes Antigens) 
class II genes [19–21]. It cooperates with DNA-bound 
complexes (RFX5/RFXAP/RFXANK and NF-YA/NF-YB/
NF-YC) and cellular coactivators forming the so-called 
HLA-II enhanceosome on HLA-II promoters. By induc-
ing the expression HLA-II molecules that serve as anti-
gen presenting molecules to CD4+ Th cells, CIITA plays 
a pivotal role in the triggering of the adaptive immune 
response [22]. The expression of HLA-II molecules is 
cell-type specific, developmentally regulated, and strictly 
correlated to the expression of CIITA. The expression 
of CIITA and of HLA-II molecules is constitutive in B 
lymphocytes, myeloid DC and thymic epithelial cells. 
Moreover, in several cell types, IFN-γ either induces or 
increases the transcription of CIITA, which, in turn, 
activates HLA-II gene expression [23, 24]. We have pre-
viously demonstrated that CIITA has an intrinsic anti-
viral activity. CIITA inhibits the replication of HIV-1 in 
human T cells by competing with the viral transactivator 
Tat for the binding to the Cyclin T1 subunit of the Posi-
tive Transcription Elongation Factor b (P-TEFb) [25]. 
Similarly, CIITA targets the viral transactivators Tax-1 
and Tax-2 of Human T cell Lymphotropic virus type-1 
and type-2 (HTLV-1 and HTLV-2), respectively, to inhibit 
viral replication by using different mechanisms [26–30]. 
Recently, we have demonstrated that CIITA inhibits also 
the persistent activation of the NF-kB pathway by Tax-1, 
thus, counteracting one of the major strategies used by 
HTLV-1 to induce T cell transformation [31]. Here, we 
investigated whether the inhibitory function of CIITA on 
Tat transactivation and, thus, HIV-1 replication occurs 
also in cells of the monocyte/macrophage cell lineage. 
To this aim we took advantage of two established U937 
promonocytic cells clones characterized by distinct func-
tional and phenotypic characteristics. The clones, named 
U937 clone 10 Plus and U937 clone 34 Minus (defined 
thereafter U937 Plus and U937 Minus, respectively) have 
been shown to be either permissive or non-permissive 
to HIV-1 replication, respectively [32]. Interestingly, a 
switch from non-permissive to permissive HIV-1 phe-
notype of U937 Minus cells was induced by vitamin D3, 
an established differentiating agent for monocytes [33]. 
The two clones have been previously used for the iden-
tification of host factors contributing to their divergent 
susceptibility to HIV-1 expression and, among other 
candidates, Tripartite Motif 22 (TRIM22) was expressed 
exclusively in U937 Minus but not in U937 Plus. In the 
same study, TRIM22 was shown to inhibit basal HIV-1 
transcription [34]. Recently, this effect was shown to be 
caused by TRIM22 interference with binding of Sp1 to its 
target DNA sequence just upstream of the transcription 
start site (+1) [35].
Here, we demonstrate that the Plus and Minus U937 
cell clones differ for the expression of all HLA-II loci 
and that this correlates with the different expression of 
CIITA. The HLA-II positive Minus cells express CIITA, 
whereas HLA-II negative Plus cells do not. More impor-
tantly, CIITA was found to be instrumental for the inhi-
bition of HIV-1 replication as U937 Plus cells stably 
transfected with CIITA (Plus-CIITA) showed a signifi-
cantly reduced capacity of supporting virus replication. 
These effects were not justified by an upregulation of 
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TRIM22 expression in Plus-CIITA cells and are, there-
fore, independent of this restriction factor. Thus, CIITA 
should be considered as an HIV-1 restriction factor also 




Plasmids expressing myc epitope-tagged CIITA full-
length (1–1130) (pcmCIITA), flag epitope-tagged CIITA 
full-length (pcfCIITA), CIITA mutants (1–321, 322–
1130, 1–285, 1–252, 253–410, 1–410, 64–285) and phRL-
CMV vector were previously described [27, 28, 36]. To 
generate pcTat expression vector, two exons-Tat cDNA 
was amplified from pRPneo-c/SL3-Tat with the follow-
ing primers: forward 5′atatatgaattcatggagccagtagatcct 
3′; reverse 5′atatatctcgagctattccttcgggcctgt 3′. The PCR 
amplified product was digested with EcoRI and XhoI 
enzymes and inserted in EcoRI/XhoI digested pcDNA3 
vector [37]. The reporter plasmid pHIV-1 LTRLuc vector 
was a gift of Prof. M. B. Peterlin (UCSF).
Cell cultures and generation of U937 Plus cells stably 
expressing CIITA
Human embryonic kidney 293T cells were maintained in 
DMEM medium. The monocytic U937 Plus and Minus 
cells and the Raji B cell line were grown in RPMI-1640 
medium supplemented with 10  % heat-inactivated fetal 
calf serum and 5 mM l-glutamine. U937 Plus cells were 
transfected with 5  μg of pcfCIITA plasmid by elec-
troporation with the GenePulser II apparatus (Bio-Rad, 
Hercules, CA) at 300  V and 250  μF. Transfected U937 
Plus-CIITA cells underwent G418 selection 1  mg/ml 
(Sigma Chemical Corp., St. Louis, MO). HLA-II DR-
positive cells were enriched by fluorescence-activated 
cell sorting with a BD FACS ARIA II cell sorter (Becton–
Dickinson, Franklin Lakes, NJ) and subjected to limiting-
dilution cloning.
Antibodies
The following monoclonal antibodies (mAb) were used 
for HLA staining: anti-HLA class I (B9.12.1), anti-HLA 
class II DR (D1.12), anti-HLA class II DP (B7/21), anti-
HLA class II DQ1 (BT/3.4), DQ2 (XIII358.4), and DQ3 
(XIV466.2). Anti-DQ mAb used recognize each mul-
tiple DQ alleles, and all together cover the entire set of 
described DQ alleles [38]. As secondary antibodies, 
either a FITC-conjugated anti mouse F(ab)2 (Sigma), or 
FITC-labeled IgG2a antibodies were used. Anti-flag-M2 
mAb and anti-tubulin polyclonal antibody were pur-
chased from Sigma. Anti-CIITA (7-1H) mAb was from 
Santa Cruz Biotechnology (Santa Cruz, CA).
Transient transfection and Luciferase (Luc) assay
For Luciferase gene reporter assays, U937 cells were 
seeded in 6 well plates (2  ×  106 cells/well) and trans-
fected with 0.6 μg of pHIV-1 LTRLuc, 0.15 μg of phRL-
CMV plasmids and increasing amounts of pcTat, by 
using FugeneHD (Promega Madison,WI). The empty 
pcDNA3.1 vector was used as a stuffer DNA to main-
tain constant the total amount of transfected DNA. 
Cell extracts were prepared 48  h post-transfection and 
assayed for Luc activities by using the dual Luc reporter 
assay system (Promega) according to the manufacturer’s 
instructions. Mean Luc values, normalized to the Renilla 
values, of at least three independent experiments per-
formed in duplicate were expressed as Tat-dependent vs 
basal fold of activation. Error bars represent the standard 
deviation.
Immunoprecipitation
CIITA protein was precipitated from 60  ×  106 U937 
Minus and Plus cells and from 30  ×  106 U937 Plus-
CIITA and Raji B cells. Cells were lysed on ice for 45 min 
with lysis buffer (1  % NP-40, 10  mM Tris–HCl pH 7.4, 
150  mM NaCl, 2  mM EDTA) supplemented with 0,1  % 
protease inhibitor cocktail (Sigma). After pre-clearing 
with protein A-Sepharose beads, whole cell extracts were 
incubated with anti-CIITA mAb for 1  h and immuno-
precipitated with protein A-Sepharose beads overnight 
at 4  °C. The precipitated proteins were resolved on 8  % 
SDS-PAGE and analyzed by Western blotting with the 
anti-CIITA mAb.
FACS analysis
The cells were collected, washed with PBS and then 
incubated with the anti-HLA antibodies for 30  min on 
ice. After washing, the cells were incubated with FITC-
labeled anti-mouse Ab for 30  min on ice. The cell sur-
face expression of HLA molecules was analyzed with an 
EPICS XL flow cytometer (Beckman Coulter, Pasadena, 
CA) and results were analyzed by the EXPO32 software 
(Beckman Coulter).
Quantification of mRNA by real‑time PCR (qRT‑PCR)
Total RNA, deriving from 2–3 independent experiments, 
was extracted from cells using TRIzol reagent (Thermo 
Fisher Scientific, Waltham, MA). cDNA was synthe-
sized from 2  μg total RNA using oligo(dT) primers and 
M-MLV reverse transcriptase (Promega). One micro-
gram of cDNA was amplified by PCR by using an ABI 
Prism 7000 sequence detection system (Thermo Fisher 
Scientific) with IQSYBR Green PCR master mix (Bio-
Rad, Hercules, CA) according to the manufacture’s proto-
col. Each reaction was performed in triplicate. All mRNA 
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values were normalized to Ribosomal Protein S7 (RPS7) 
mRNA. The following primer pair sets were used: CIITA 
forward 5′-cctgctgttcgggacctaaaa-3′; reverse primer, 
5′-ggatccgcaccagtttgg-3′; TRIM22, forward 5′-cactcttctc-
ccctgattcaa-3′, reverse 5′-tcacaaactcctgcagtgct-3′; HLA-
II DR, forward 5′-ctcttctcaagcactgggagttt-3′, reverse 
5′-atgaagatggtcccaataatgatg-3′; RPS7, forward 5′-tggaga-
tgaactcggacctc-3′, reverse 5′-cgaccaccaccaacttcaa-3′.
Infection and quantitative PCR analysis of HIV‑1 proviral 
DNA
U937 cells were exposed to the laboratory-adapted 
CXCR4-dependent HIV-1IIIB/LAI virus at the multiplicity 
of infection (moi) of 1. After 1  h of virus adsorption at 
37  °C, the cells were resuspended in complete medium 
and seeded at 5 ×  105 cells/well in triplicate in 96-well 
tissue culture plates. Culture supernatants were har-
vested up to 41  days and stored at −80  °C until tested 
for Mg2+  -dependent reverse transcriptase (RT) activ-
ity assay, as previously described [34]. Total HIV-1 DNA 
was quantified by qRT-PCR with an ABI 7700 prism 
instrument (Thermo Fisher Scientific), using prim-
ers and a probe that recognize the HIV-1 gag gene: 
forward 5′-acatcaagccatgcaaat-3′; reverse 5′-atctggcctg-
gtgcaatagg-3′; and probe 5′-(FAM) catcaatgaggaagct-
gcagaatgggataga (TAMRA)-3′. The number of HIV-1 
DNA copies was normalized to that of human GAPDH 
by an external standard curve showing a linear distribu-
tion (r =  0.99) between 10 and 106 copies. The primers 
and probe for GAPDH were: forward 5′-accacagtccatg-
catcact-3′; reverse 5′-ggccatcacgccacagtt-3′; and probe, 
5′-(FAM) cccagaagactgtggatggcccc (TAMRA)-3′.
Statistical analysis
A statistical analysis was performed using the GraphPad 
Prism software v. 6.0 (GraphPad Software, http://www.
graphpad.com). Comparison between two groups was 
performed by using the unpaired t test. P values  <0.05 
were considered significant.
Results
Lack of CIITA expression is responsible for the 
HLA‑II‑negative phenotype of U937 Plus cells
To verify that the two U937 Plus and Minus isogenic 
cell clones differ for the HLA-II cell surface expression, 
we firstly assessed the complete HLA-II phenotype by 
immunofluorescence staining and FACS analysis. HLA-
II DR was not expressed by U937 Plus cells, whereas it 
was expressed by U937 Minus cells although at lower 
levels compared to Raji B cell line (Fig.  1a). Similarly, 
HLA-II DP and HLA-II DQ2 were expressed in U937 
Minus cells but not in U937 Plus cells. Conversely, both 
U937 cell clones expressed HLA class-I molecules on 
their cell surface (Fig. 1a). To verify whether the lack of 
HLA-II molecules in U937 Plus cells was due to a tran-
scriptional defect, we measured the amount of HLA-II 
DR mRNA by qRT-PCR. According to the expression of 
HLA-II DR molecules, we detected HLA-II DR mRNA 
in Minus but not in Plus U937 cells (Fig. 1b). Thus, we 
concluded that the complete set of HLA-II molecules 
was not expressed on the surface of U937 Plus cells 
consequently to a block in HLA-II genes transcription. 
As HLA-II expression is regulated at transcriptional 
level by several factors, but is strictly dependent on the 
presence of CIITA, we next investigated whether the 
different HLA-II phenotype of the two U937 clones 
correlated with a different expression of CIITA. To this 
aim, we quantified CIITA mRNA levels in both U937 
clones by qRT-PCR and found that only U937 Minus 
cells expressed CIITA mRNA, whereas U937 Plus cells 
did not (Fig.  1b). Overall, these data demonstrate that 
CIITA expression or lack of it marks a clear-cut dis-
tinction between U937 Minus (CIITA-positive) and 
U937 Plus (CIITA-negative) cells. In addition, these 
results indicated that this cellular model represented 
by isogenic cell clones naturally differing for CIITA 
expression is suitable to define the anti-viral role of this 
molecule in HIV-1 infection of myeloid cells.
Generation of U937 Plus cells stably expressing CIITA
Although U937 cell clones differ for the expression of 
CIITA, we cannot exclude that other factors could con-
tribute to their divergent capacity to sustain productive 
HIV-1 infection. Thus, to clarify the role of CIITA in 
HIV-1 restriction we generated U937 Plus cells express-
ing exogenous CIITA. The expression vector of flag 
epitope-tagged CIITA was stably transfected in the 
CIITA-negative U937 Plus parental cells. Transfected 
cells were selected with antibiotics and analyzed by 
immunofluorescence and cytofluorometry for HLA-
II DR expression. A large proportion of cells expressed 
HLA-DR, demonstrating that CIITA alone was able to 
induce the expression of HLA-II genes (Fig.  2a). Highly 
expressing HLA-II DR cells were isolated by limiting dilu-
tion cloning and two HLA-II DR-positive clones (1C11, 
1F6) and one negative clone (4G2) were selected for sub-
sequent analyses (Fig. 2a). According to their HLA-II DR 
cell surface expression, the U937 cell clones 1C11 and 
1F6 expressed higher levels of HLA-II DR mRNA com-
pared to U937 Minus cells.
Similarly to U937 Plus cells, the negative clone 4G2 did 
not express DR mRNA (Fig. 2b).
Finally, the levels of CIITA protein expression in 1C11 
and 1F6 cell clones were comparable to those of the 
control Raji B cell line as determined by immunopre-
cipitation and Western blotting (Fig.  2c, lanes 3–4 vs 
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lane 6, respectively). The expression of CIITA in Plus-
CIITA cells was higher than that of U937 Minus cells 
(Fig.  2c, lanes 3–4 vs lane 2) because twice the amount 
of U937 Minus cell lysate was needed to detect levels of 
CIITA similar to those found in clones 1C11 and 1F6 
(Fig.  2c, lanes 3–4 vs lane 2). As expected, CIITA was 
not detected in the parental U937 Plus cells (Fig. 2c, lane 
1) and in the HLA-II-negative 4G2 clone (Fig.  2c, lane 
5). Thus, CIITA-positive U937 Plus cells represent an 
important tool to uncouple the role of CIITA from other 
factors which may also contribute to HIV-1 restriction in 
monocytic cells.
Fig. 1 U937 Minus cells, but not U937 Plus cells express HLA-II and CIITA. a HLA-I and HLA-II phenotyping of U937 Minus and U937 Plus cells 
was carried out by immunofluorescence and FACS analysis. Raji B cells were used as a positive control for both HLA-I and HLA-II expression. 
Histograms represent fluorescence profiles of the cells indicated on the left, incubated with specific anti HLA-I or HLA-II mAbs (solid line) or with 
FITC-conjugated F(ab)2 anti mouse antibody (dashed line). By using three mAbs each covering subgroups (DQ1, DQ2 and DQ3) of DQ molecules 
we found that U937 Minus cells are DQ2-positive. Mean fluorescence (mf ) values are expressed in the abscissa as arbitrary units (au). b HLA-II DR 
and CIITA mRNAs expression in U937 Minus cells, U937 Plus cells and Raji B cells was assessed by qRT-PCR. The results of a representative experi-
ment performed in triplicates are shown. CIITA and HLA-II DR mRNA levels are expressed as values relative to those of Minus cells set to 1. Raji B 
cells were used as a positive control for both CIITA and HLA-II DR mRNA expression. Unpaired two-tailed t test has been performed (****P < 0.0001; 
***P = 0.0001). Error bars represent the standard deviation
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Fig. 2 Cellular and molecular characterization of U937 Plus cells stably expressing exogenous CIITA. a U937 Plus cells were stably transfected with 
pcfCIITA vector expressing flag-tagged CIITA, generating Plus-CIITA cells. Bulk population was analyzed for HLA-II DR expression by FACS analysis. 
HLA-II-positive clones were isolated by sorting and cloning. FITC-conjugated isotype-matched secondary antibody (IgG2a) (dotted line) represents 
the negative control. b HLA-II DR mRNA expression was assessed by qRT-PCR in U937 Minus cells, U937 Plus cells and in clones 1C11, 1F6, 4G2. 
The results of a representative experiment performed in triplicates are shown. mRNA values are expressed relatively to that of Minus cells set to 1. 
Unpaired two-tailed t test has been performed (****P < 0.0001; ***P < 0.005). Error bars represent the standard deviation. c Cell lysates obtained 
from U937 Plus cells (60 × 106 cells) (lane 1), U937 Minus cells (60 × 106 cells) (lane 2) and CIITA-transfected Plus clones (30 × 106 cells) (lanes 
3–5) were immunoprecipitated with an anti-CIITA antibody (IP a CIITA) and analyzed for the presence of CIITA by western blotting. Raji cell lysate 
(30 × 106 cells) was used as a positive control of CIITA expression (lane 6). Eight percent of the pre-cleared cell lysates was analyzed for the expres-
sion of α-tubulin by western blotting (input)
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Tat‑mediated HIV‑1 LTR transactivation occurs in U937 Plus 
cells but is suppressed in U937 Minus cells and in U937 
Plus‑CIITA clones
We have previously demonstrated that CIITA inhibits 
HIV-1 replication in human T cells by interfering with 
Tat function [25]. Therefore, we investigated whether 
the HIV-1 permissive and non-permissive phenotypes 
of U937 Plus and Minus cells, respectively, were due to 
their capacity to support or inhibit Tat-dependent HIV-1 
LTR transactivation as a consequence of their different 
expression of CIITA. To this aim, we measured the Tat-
dependent luciferase activities in U937 Minus, Plus and 
Plus-CIITA cells transiently transfected with the pHIV-
1LTR-Luc reporter gene and increasing amounts of Tat 
expressing vector. An efficient Tat-dependent transacti-
vation of HIV-1 transcription was observed in U937 Plus 
cells, whereas it was significantly reduced in the U937 
Minus cells at both doses of Tat (Fig.  3, grey and black 
columns, respectively). Remarkably, in U937 Plus-CIITA 
clones 1C11 and 1F6 transfected with the highest amount 
of Tat plasmid, Tat transactivation is inhibited similarly 
to U937 Minus cells. In the 4G2 cell clone devoid of 
CIITA expression, Tat-mediated HIV-1 LTR transactiva-
tion was unaffected (Fig.  3). These results indicate that 
the permissive and the non-permissive phenotypes to 
HIV-1 infection of U937 Plus and Minus cells correlate 
with their capacity or incapacity, respectively, to support 
Tat-mediated HIV-1 LTR transcription. Importantly, the 
stable expression of CIITA in Plus cells abrogated Tat 
transactivating function. Thus, CIITA plays a major role 
in the inhibition of Tat transactivation, not only in T cells 
but also in myeloid cells, at least in the cellular model 
here investigated.
CIITA region 64–285 is required for the inhibition 
of Tat‑dependent activation of the HIV‑1 LTR
CIITA is a protein composed of 1130 amino acids, con-
taining several functional domains regulating its biologi-
cal activity. To define the region(s) of CIITA responsible 
for inhibiting the activation of the HIV-1 promoter by 
Tat, several deletion mutants of CIITA were expressed in 
293T cells and analyzed for their ability to suppress Tat-
promoted HIV-1 LTR-dependent luciferase activities in 
comparison to full-length CIITA. Confirming the results 
obtained in CIITA-positive U937 cells, CIITA full-
length inhibited Tat activity in a dose-dependent manner 
(Fig. 4a, lanes 3–5 vs lane 2). By using two complemen-
tary CIITA fragments, 1-321 and 322–1130, we deter-
mined that the N-terminal 1–321, but not the C-terminal 
322–1130 deletion mutant, inhibited Tat activity (Fig. 4a, 
lanes 6–8 and lanes 9–11, respectively). Thus, we focused 
on the N-terminal part of CIITA to restrict the region 
mediating its inhibitory effect. The mutant encompass-
ing amino acids 1–285 still inhibited Tat function, simi-
larly to CIITA 1–321 (Fig. 4a, lanes 12–14 vs lane 2). On 
the contrary, CIITA 1-252 did not exert any suppressive 
effect (Fig. 4a, lanes 15–17 vs lane 2) indicating that resi-
dues 253–285 were crucial for the inhibition of Tat func-
tion (Fig. 4b, black box). Surprisingly enough, the CIITA 
fragment 253–410, containing the inhibitory domain, did 
not block LTR transactivation by Tat (Fig. 4a, lanes 18–20 
vs lane 2), suggesting that the inhibitory domain 253–285 
must be extended at the N-terminus in order to accom-
plish its suppressive effect. Indeed, the extension of frag-
ment 253–410 to residue 1 rescued the ability to inhibit 
Tat by CIITA 1-410 (Fig.  4a, lanes 21–23 vs lane 2). Of 
interest, the deletion of the first 63 amino acids in CIITA 
1–285 did not abrogate its capacity to suppress Tat activ-
ity (Fig. 4a, lanes 24–26 vs lane 2). Overall, these results 
show that the CIITA region encompassing residues 
64–285 is the minimal domain required for the inhibition 
of Tat-dependent LTR transactivation.
HIV‑1 replication is inhibited in U937 Plus‑CIITA cells
To assess whether the CIITA-mediated inhibition of 
Tat function observed in CIITA-positive U937 cells was 
correlated with an inhibition of HIV-1 replication we 
infected the different U937 clones with HIV-1IIIB/LAI and 
measured the levels of RT viral activity in the culture 
supernatants up to 41 days post-infection. As previously 
Fig. 3 CIITA inhibits Tat transactivating function in U937 Minus cells 
and in U937 Plus-CIITA clones. U937 Minus (black columns) and U937 
Plus (gray columns) cells were co-transfected with fixed amount of 
pHIV-1 LTR-Luc, phRL-CMV, and increasing amounts (10, 20 ng) of 
plasmid coding for Tat (pcTat). CIITA-positive Plus clones 1C11, 1F6 
and CIITA-negative Plus 4G2 clone were co-transfected with fixed 
amount of pHIV-1 LTR-Luc, phRL-CMV and 20 ng of pcTat. The basal 
HIV-1 LTR activity was set to 1 for each cell (−). Mean luciferase values, 
normalized to Renilla values, are presented as fold of activation (Tat-
dependent vs basal). Results are the average of two independent 
experiments (**P < 0.005, unpaired two-tailed t test). Error bars show 
standard deviation
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shown [32, 34], HIV-1 replicates efficiently in U937 Plus 
cells reaching a peak at day 27 (Fig. 5a, solid lane, open 
circle). In contrast, virus replication in U937 Minus cells 
was not detected in this time frame (Fig.  5a, solid lane, 
solid square), consistently with previous publications 
[34]. Of note, in CIITA-expressing U937 Plus clone 1F6 
the HIV-1 replication was significantly inhibited with 
respect to U937 Plus cells (Fig. 5a, dashed lane, solid tri-
angle). In particular, at day 27 the RT activity measured 
in U937 Plus-CIITA 1F6 clone was less than 40  % the 
one measured in U937 Plus cells (6.318 and 16.534 cpm/
μl, respectively). This different profile of virus replica-
tion was not accounted for by a different infection effi-
ciency in that the amount of HIV-1 DNA detected 24 h 
post-infection was comparable in all tested cells (Fig. 5b). 
In conclusion, the results obtained by infecting U937 
Plus-CIITA clone 1F6, indicate that CIITA contributes, 
at least in part, in determining the non-permissive phe-
notype of U937 Minus cells by inhibiting Tat activity. In 
U937 Plus-CIITA 1F6 clone, HIV-1 replication was sig-
nificantly suppressed compared with Plus parental cells, 
but did not reach the inhibition level observed in Minus 
cells (Fig. 5a). This result let us to hypothesize that other 
host factors with anti-viral functions may contribute to 
the non-permissive phenotype of Minus cells. Among 
these, TRIM22, expressed in U937 Minus cells, but not 
in U937 Plus cells, was shown to inhibit basal as well 
as PMA plus ionomycin-induced HIV-1 transcription 
Fig. 4 Residues 253-285 of CIITA are essential but not sufficient to inhibit Tat-mediated HIV-1 LTR transactivation. a 293T cells were co-transfected 
with fixed amounts of pHIV-1LTR Luc, phRL-CMV, pTat and increasing amounts of flag-tagged CIITA full-length or the deletion mutants listed below 
the western blot analyses. The results of a representative experiment are shown. Mean luciferase activities, normalized to Renilla activity, are pre-
sented as percentages relative to activation by Tat set to 100 % (black column 2). Column 1 represents the basal activity of cells transfected with the 
pcDNA3 vector. The expression of recombinant fCIITA proteins in cell extracts was evaluated by anti-flag western blotting. b Schematic representa-
tion of the results of the gene reported assay illustrated in panel a. CIITA proteins used for the mapping are shown, along with their capacity to 
inhibit Tat-dependent activation of LTR promoter (+). The endpoints of CIITA full-length and CIITA deletion mutants are indicated. At the top is a 
diagram of CIITA with its domains, labeled as follows: AD activation domain, P/S/T proline/serine/threonine-rich domain, GBD GTP-binding domain, 
and LRR leucine-rich repeats
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independently of Tat and NF-kB [34]. Therefore, we veri-
fied whether CIITA transfection in Plus cells induced 
TRIM22 mRNA as quantified by qRT-PCR. We found 
that only U937 Minus cells expressed TRIM22 mRNA 
whereas CIITA-positive 1C11 and 1F6 clones as well as 
the CIITA-negative 4G2 clone did not (Fig. 5c). Thus, in 
CIITA-expressing U937 Plus clones, the impairment of 
HIV-1 replication is solely due to CIITA and not to the 
induction of TRIM22 expression.
It has been reported that the treatment of U937 Minus 
cells with 1,25 Dihydroxyvitamin D3 (Vitamin D3) con-
verts their non-permissive phenotype in the permis-
sive one [33]. Therefore, we assessed whether Vitamin 
D3 treatment was also associated with the modification 
of CIITA and HLA-II expression in Minus cells. Indeed, 
Vitamin D3 induced a strong down-regulation of CIITA 
mRNA and, by consequence, of HLA-II (Fig. 5d). These 
results suggest that in Vitamin D3-treated Minus cells, 
the down-regulation of CIITA expression, could contrib-
ute to the previously shown increased susceptibility to 
HIV-1 productive infection [33].
Discussion
We have previously demonstrated that CIITA, the mas-
ter regulator of HLA-II gene transcription, inhibits 
HIV-1 replication in CD4+ human T cell lines express-
ing exogenous CIITA. This inhibition occurs by prevent-
ing the binding of HIV-1 Tat to the Cyclin T1 subunit of 
the P-TEFb complex, used by the virus to elongate the 
viral transcripts. In this study, we used two established 
U937 cell clones to investigate whether CIITA inhib-
its HIV-1 replication also in the monocytic cells. CIITA 
was expressed in the HIV-1-non-permissive U937 clone 
34 Minus, but not in the HIV-1-permissive U937 clone 
Fig. 5 CIITA stably expressed in U937 Plus cells inhibits HIV-1 replication without inducing TRIM22 transcription. a U937 Minus cells, U937 Plus cells 
and U937 Plus-CIITA 1F6 clone were infected with HIV-1IIIB/LAI and viral replication was measured by monitoring RT activity in the culture superna-
tants up to 41 days post-infection (pi) Mean values of triplicate cultures are shown. The data are representative of four independent experiments. 
b At 24 h pi the amount of HIV-1 proviral DNA was assessed by real time PCR by using primers specific for gag. c TRIM22 mRNA expression was 
assessed by qRT-PCR in U937 Minus cells, U937 Plus cells and in clones 1C11, 1F6, 4G2. U937 Minus cells TRIM22 mRNA level was set to 1. d U937 
Minus cells either untreated (−) or treated (+) with 10 nM vitamin D3 for 72 h were analyzed for CIITA and HLA-II DR mRNAs expression by qRT-PCR. 
In Vitamin D3-untreated U937 Minus cells the amount of both CIITA and HLA-II DR mRNAs was set to 1. Results are the average of three independ-
ent experiments (***P = 0.0001; **P = 0.0094, unpaired two-tailed t test). Error bars show standard deviation
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10 Plus, and this strongly correlated with the inhibition 
of Tat-mediated HIV-1 LTR transactivation in Minus 
but not in Plus clone. To substantiate this hypothesis we 
have modified U937 Plus cells by introducing a genetic 
cassette expressing exogenous CIITA. The expression of 
CIITA in modified U937 Plus cells significantly reduced 
the Tat transactivating function in comparison to the 
U937 Plus parental cell line. This finding suggested a 
prominent role of CIITA in HIV-1 restriction in mono-
cytic cells. The expression of CIITA alone significantly 
reduced HIV-1 replication in Plus-CIITA cells compared 
to U937 Plus parental cells. However, the potency of inhi-
bition of HIV-1 replication in Plus-CIITA cells did not 
reach that observed in U937 Minus cells supporting the 
hypothesis that other factors cooperate with CIITA in 
determining the long lasting restriction of virus replica-
tion typical of U937 Minus cells.
In this regard the host restriction factor TRIM22, as 
CIITA, is expressed exclusively in U937 Minus cells and 
it was shown to inhibit basal as well as PMA+  ionomi-
cyn induced HIV-1 transcription [34]. Therefore, we 
ruled out the possibility that CIITA transfection caused 
an upregulated expression of TRIM22 and concluded 
that these two factors act independently and, at least 
potentially, synergistically, in terms of inhibiting viral 
transcription and replication. By comparing the effect 
on virus replication of CIITA and TRIM22, it should be 
noted that the levels of inhibition in U937 Plus cells was 
comparable upon transduction of either TRIM22 [34] or 
CIITA and that neither factor alone could account for the 
extremely restricted phenotype of U937 Minus cell clone. 
Future studies aimed at identifying the possible func-
tional relationship between these two factors will bring 
further insight into the molecular mechanism involved in 
HIV-1 restriction.
It has been shown that Vitamin D3 stimulation pro-
motes HIV-1 replication in U937 Minus cells by reverting 
the non-permissive phenotype to a permissive one. This 
effect was partially attributed to an increased expression 
of CXCR4 and increased viral entry, although other fac-
tors have been suggested to be involved in the induction 
of the permissive phenotype [33]. Moreover, Vitamin 
D3 treatment has been shown to negatively modulate 
the expression of HLA-II genes in IFN-γ-treated cells 
[39] and, particularly, in human blood circulating mono-
cytes [40]. Finally, it has also been shown that in Vita-
min D3-treated U937 cells the expression of HLA-II 
was down-modulated with respect to the untreated cells 
[41]. The above observations did not explain the inti-
mate mechanism at the basis of this down-modulation. 
Here, we demonstrated that the decreased expression 
of HLA-II molecules in U937 Minus cells after Vitamin 
D3 treatment is due to the transcriptional impairment of 
both HLA-II structural genes and their transcriptional 
regulator CIITA. Overall, these findings further reinforce 
the association between CIITA expression and the inhi-
bition of HIV-1 replication in monocytic compartment.
CIITA is a large protein of 1130 amino acids and it 
was interesting to assess whether only the full-length 
molecule or a part of it could inhibit Tat function. 
We used several N-terminal and C-terminal dele-
tion mutants of CIITA to map the region responsible 
for the inhibition of Tat activity. A short stretch of 
32 amino acids from positions 253 to 285 was strictly 
required for the inhibitory effect of CIITA. Remark-
ably, this amino acid sequence needed to be extended 
at the N-terminus to exert the inhibitory function. It 
has been shown that Cyclin T1 of the P-TEFb complex 
binds to the first 322 amino acids of CIITA [42]. Thus, 
it is possible that the extension to the N-terminus of 
the inhibitory domain identified by our functional 
mapping, is necessary for a correct folding of CIITA, 
in order to bind Cyclin T1. Interestingly enough, this 
region does not correspond to that involved in the 
inhibition of HTLV-1 Tax-1- and HTLV-2 Tax-2-me-
diated LTR transactivation [27, 28], indicating that 
CIITA exploits different mechanisms for the inhibition 
of the different retroviral transactivators.
Although macrophages and CD4+  T cells are both 
major targets of HIV-1, the susceptibility to viral infec-
tion is different in the two cell types and depends on the 
activation status of the cells [43, 44]. Multiple cellular 
factors may be limiting for productive HIV-1 infection 
in these cells. Among these the P-TEFb complex, result-
ing from Cyclin T1 and CDK9 heterodimeric association, 
is essential for Tat function [42]. P-TEFb is differentially 
expressed in CD4+  T lymphocytes and monocytes/
macrophages, depending on their activation and differ-
entiation status [45]. Therefore, it is conceivable that the 
inhibition of Tat activity by CIITA may be influenced 
not only by the squelching of Cyclin T1 by CIITA but 
also by the modulation of Cyclin T1 expression itself in 
myeloid cells. Within this frame, it has been shown that 
PMA treatment, a stimulus inducing the differentiation 
of U937 promonocytic cells into macrophage-like cells 
results in increased levels of HIV-1 replication and Cyclin 
T1 expression [46]. Remarkably, we previously showed 
that in PMA-differentiated U937 cells, the mRNA levels 
of both HLA-II and CIITA are strongly down-regulated 
with respect to control unstimulated cells [47]. Thus, the 
increased susceptibility to HIV-1 productive infection 
in PMA-treated U937 cells may correlate both with the 
increase of Cyclin T1 and with the down-regulation of 
CIITA restriction factor.
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Conclusions
In conclusion our findings confirm and extend the knowl-
edge on the role of CIITA acting as a restriction factor 
for HIV-1. Unlike other host restriction factors, CIITA 
has the peculiar characteristic of both activating the 
adaptive immune response to pathogens and suppress-
ing viral gene expression by targeting the activity of the 
viral transactivators. This dual function of CIITA against 
retroviruses operates not only in T cells [25, 48], but also 
in the monocyte-macrophage cell lineage, endowed with 
both adaptive and intrinsic immune functions.
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